Nuwellis publishes study on reduction of heart failure readmissions with Aquadex

Nuwellis announces the publication of a new study in Current Problems in Cardiology demonstrating the effectiveness of Aquadex ultrafiltration therapy in reducing 60 day hospital readmission rates for patients with acutely decompensated heart failure or ADHF, who are otherwise resistant to diuretic treatment. Significant Volume Loss and Weight Reduction: Patients experienced significant volume loss and weight reduction without adverse renal effects. Significant Reduction in Heart Failure Readmissions: The study found a statistically significant reduction in rehospitalization rates for heart failure at 60 days from the initiation of ultrafiltration therapy compared to the pre-ultrafiltration period…”This study underscores the value of ultrafiltration therapy with Aquadex in managing fluid overload in hospitalized heart failure patients,” commented Nestor Jaramillo, President and CEO of Nuwellis. “The positive outcomes reported in this community-based hospital setting demonstrate the broader applicability and effectiveness of Aquadex, which is critical as we continue to expand access to this life-saving therapy in multiple academic and community healthcare centers across the country.” Mr. Jaramillo added, “These study results should be of interest to the many physicians and hospital administrators seeking to reduce the losses associated with heart failure patient care. The statistically significant outcomes reported in this study further reinforce the value of Aquadex. This new evidence comes as we marked 30% revenue growth in our core business, as reported in our second quarter earnings release.”